Therapeutic Area | MeSH |
---|---|
nutritional and metabolic diseases | D009750 |
Brand Name | Status | Last Update |
---|---|---|
veltassa | New Drug Application | 2025-01-31 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
hyperkalemia | — | D006947 | E87.5 |
Patent | Expires | Flag | FDA Information |
---|---|---|---|
Patiromer Sorbitex Calcium, Veltassa, Vifor Pharma | |||
9492476 | 2033-10-08 | U-1766 | |
9925212 | 2033-10-08 | U-1766 | |
11123363 | 2033-10-08 | U-1766 | |
8337824 | 2030-05-29 | DP | U-1766 |
8147873 | 2028-06-20 | DP | |
8282913 | 2027-05-29 | DP | |
8216560 | 2027-03-14 | U-1766 | |
7556799 | 2025-02-27 | U-1766 | |
8287847 | 2024-03-30 | U-1766 | |
8475780 | 2024-03-30 | U-1766 | |
8778324 | 2024-03-30 | U-1766 | |
8889115 | 2024-03-30 | U-1766 | |
10485821 | 2024-03-30 | U-1766 |
Drug common name | Patiromer |
INN | patiromer calcium |
Description | Patiromer, sold under the brand name Veltassa, is a medication used to treat high blood potassium. It is taken by mouth. It works by binding potassium in the gut.
|
Classification | Small molecule |
Drug class | polymers; antihyperlipidemic, thyromimetic derivatives |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL2107875 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | DB09263 |
UNII ID | 1FQ2RY5YHH (ChemIDplus, GSRS) |